Nanotechnology Now - Press Release: Senesco Expands on Preclinical Multiple Myeloma Findings

Home > Press > Senesco Expands on Preclinical Multiple Myeloma Findings

Abstract:
Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced today
further details of its continuing preclinical multiple myeloma research. In
February 2008, the Company announced results of preclinical animal studies in
which Senesco's Factor 5A technology, encapsulated in nanoparticles, was able
to induce apoptosis in multiple myeloma tumors when injected intratumorally.

Senesco Expands on Preclinical Multiple Myeloma Findings

NEW BRUNSWICK, NJ | Posted on June 5th, 2008

Senesco has continued its research in both preclinical animal models and
human multiple myeloma cell lines, while also studying intravenous delivery of
its therapy. In its previously announced preclinical testing and its recent
expanded studies, the Company has used a combination therapy of its siRNA
against Factor 5A, as well as a plasmid of the Factor 5A gene encapsulated in
a nanoparticle.

Whether the combination therapy was injected intratumorally or
systemically, human multiple myeloma tumors grown subcutaneously in the flanks
of immunodeficient mice were reduced by approximately 95% versus tumors in
untreated mice. Additionally, groups of treated mice were studied for up to
three weeks after the last therapeutic injection and in mice whose tumors had
regressed, the tumors did not regenerate.

In human multiple myeloma cell line studies, Senesco determined that its
siRNA may sensitize cells for apoptosis through a reduction in activation of
NFkB, a key inflammatory transcription factor. The siRNA also reduced levels
of ICAM (intracellular adhesion molecule), a binding molecule, which is
involved in promoting tissue inflammation.

The Company, together with its clinical research organization, is
evaluating potential manufacturing centers for its materials, planning
preclinical toxicology studies and continuing preclinical disease model
studies.

####

About Senesco Technologies, Inc.
Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered
in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or
delay cell death in mammals (apoptosis) to determine if the technology is
applicable in human medicine. Accelerating apoptosis may have applications to
development of cancer treatments. Delaying apoptosis may have applications to
certain inflammatory and ischemic diseases. Senesco takes its name from the
scientific term for the aging of plant cells: senescence. Delaying cell
breakdown in plants extends freshness after harvesting, while increasing crop
yields, plant size and resistance to environmental stress. The Company
believes that its technology can be used to develop superior strains of crops
without any modification other than delaying natural plant senescence.
Senesco has partnered with leading-edge companies engaged in agricultural
biotechnology and earns research and development fees for applying its
gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Actual results could differ materially from such statements
expressed or implied herein as a result of a variety of factors, including,
but not limited to: the development of the Company's gene technology; the
approval of the Company's patent applications; the successful implementation
of the Company's research and development programs and joint ventures; the
success of the Company's license agreements; the acceptance by the market of
the Company's products; success of the Company's preliminary studies and
preclinical research; competition and the timing of projects and trends in
future operating performance, our ability to maintain our continued listing
standards for the next 12 months, as well as other factors expressed from time
to time in the Company's periodic filings with the Securities and Exchange
Commission (the "SEC"). As a result, this press release should be read in
conjunction with the Company's periodic filings with the SEC. The forward-
looking statements contained herein are made only as of the date of this press
release, and the Company undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.

For more information, please click here

Contacts:
Senesco Technologies, Inc.
Bruce Galton
Chief Executive Officer
( )
(732) 296-8400

Investor Relations Contact:
FD
Brian Ritchie
( )
(212) 850-5600